Summary
1.29 -0.01(-0.77%)07/05/2024
CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc (CTMX)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
-1.15 | 5.31 | -22.99 | -37.53 | -14.57 | -28.33 | -88.51 | -90.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 1.29 | |
Open | 1.30 | |
High | 1.31 | |
Low | 1.27 | |
Volume | 373,821 | |
Change | -0.02 | |
Change % | -1.15 | |
Avg Volume (20 Days) | 1,549,452 | |
Volume/Avg Volume (20 Days) Ratio | 0.24 | |
52 Week Range | 1.04 - 5.85 | |
Price vs 52 Week High | -77.95% | |
Price vs 52 Week Low | 24.04% | |
Range | -0.77 | |
Gap Up/Down | -0.06 |
Fundamentals | ||
Market Capitalization (Mln) | 101 | |
EBIDTA | -94,456,000 | |
PE Ratio | 0.0000 | |
PEG Ratio | -1.8000 | |
WallStreet Target Price | 13.50 | |
Book Value | 1.7120 | |
Earnings Per Share | -1.2120 | |
EPS Estimate Current Quarter | -0.3100 | |
EPS Estimate Next Quarter | -0.2300 | |
EPS Estimate Current Year | -1.1600 | |
EPS Estimate Next Year | -1.5600 | |
Diluted EPS (TTM) | -1.2120 | |
Revenues | ||
Profit Marging | -1.0885 | |
Operating Marging (TTM) | -1.0911 | |
Return on asset (TTM) | -0.1210 | |
Return on equity (TTM) | -0.9025 | |
Revenue TTM | 66,219,000 | |
Revenue per share TTM | 1.1130 | |
Quarterly Revenue Growth (YOY) | -0.0110 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 100,362,000 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 3.6751 | |
Revenue Enterprise Value | 2.9698 | |
EBITDA Enterprise Value | 0.5098 | |
Shares | ||
Shares Outstanding | 65,249,100 | |
Shares Float | 48,117,308 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.00 | |
Insider (%) | 1.30 | |
Institutions (%) | 93.10 |
06/18 08:00 EST - globenewswire.com
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.
06/17 16:15 EST - globenewswire.com
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.
CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.
06/05 06:00 EST - investorplace.com
Buy Alert: 3 Penny Stocks That Will Explode in 2024
When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience.
Buy Alert: 3 Penny Stocks That Will Explode in 2024
When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience.
05/29 06:25 EST - investorplace.com
No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock took a round trip from $1.80 to $5.80 and back.
No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock took a round trip from $1.80 to $5.80 and back.
05/22 16:05 EST - globenewswire.com
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.
05/16 16:15 EST - globenewswire.com
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.
05/09 11:56 EST - investorplace.com
Why Is CytomX (CTMX) Stock Down 43% Today?
CytomX Therapeutics (NASDAQ: CTMX ) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company. CytomX Therapeutics latest clinical trail update covers its Phase 1a study of CX-904.
Why Is CytomX (CTMX) Stock Down 43% Today?
CytomX Therapeutics (NASDAQ: CTMX ) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company. CytomX Therapeutics latest clinical trail update covers its Phase 1a study of CX-904.
05/09 09:10 EST - invezz.com
CytomX stock down 30% despite encouraging cancer study results
CytomX Therapeutics Inc reported favourable results for its ongoing trial of CX-904 on Thursday. Shares of the biotech firm are still down about 30% at writing.
CytomX stock down 30% despite encouraging cancer study results
CytomX Therapeutics Inc reported favourable results for its ongoing trial of CX-904 on Thursday. Shares of the biotech firm are still down about 30% at writing.
05/08 16:10 EST - globenewswire.com
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall -
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall -
05/08 16:10 EST - globenewswire.com
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -
05/07 16:15 EST - globenewswire.com
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -
05/02 09:11 EST - zacks.com
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
05/01 11:43 EST - investorplace.com
Why Is CytomX (CTMX) Stock Up 180% Today?
CytomX (NASDAQ: CTMX ) stock is rocketing higher on Wednesday after the company provided investors with an update for its upcoming earnings report. The oncology-focused biopharmaceutical company told traders that it will release its earnings report for the first quarter of 2024 when markets close on May 8, 2024.
Why Is CytomX (CTMX) Stock Up 180% Today?
CytomX (NASDAQ: CTMX ) stock is rocketing higher on Wednesday after the company provided investors with an update for its upcoming earnings report. The oncology-focused biopharmaceutical company told traders that it will release its earnings report for the first quarter of 2024 when markets close on May 8, 2024.
05/01 08:00 EST - globenewswire.com
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study -
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study -
04/25 18:33 EST - seekingalpha.com
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. Their main pipeline candidate, CX-904, is a bispecific "probody" targeting EGFR and CD3, being assessed in a phase 1 trial. The company has a strategic collaboration with Amgen for CX-904 and with Astellas for CX-2051, an antibody-drug conjugate targeting EpCAM.
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
CytomX Therapeutics is a biotech company developing anticancer therapeutics using a technology that activates an immune response within the tumor microenvironment. Their main pipeline candidate, CX-904, is a bispecific "probody" targeting EGFR and CD3, being assessed in a phase 1 trial. The company has a strategic collaboration with Amgen for CX-904 and with Astellas for CX-2051, an antibody-drug conjugate targeting EpCAM.
04/23 14:21 EST - zacks.com
GSK Gears Up for Q1 Earnings: Here's What to Expect
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
GSK Gears Up for Q1 Earnings: Here's What to Expect
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
04/08 08:00 EST - globenewswire.com
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across many cancer types including colorectal, gastric, endometrial, and ovarian cancers. The cytotoxic payload utilized in CX-2051 is a derivative of camptothecin, a topoisomerase-1 inhibitor, a class of drug that has shown potent clinical anti-cancer activity and demonstrated significant clinical benefit as an approved ADC in multiple cancers. The CX-2051 Phase 1 dose escalation is designed to efficiently test the safety and preliminary anti-tumor activity of CX-2051, to provide initial clinical proof of concept to inform a potential decision to move into dose expansions in 2025.
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across many cancer types including colorectal, gastric, endometrial, and ovarian cancers. The cytotoxic payload utilized in CX-2051 is a derivative of camptothecin, a topoisomerase-1 inhibitor, a class of drug that has shown potent clinical anti-cancer activity and demonstrated significant clinical benefit as an approved ADC in multiple cancers. The CX-2051 Phase 1 dose escalation is designed to efficiently test the safety and preliminary anti-tumor activity of CX-2051, to provide initial clinical proof of concept to inform a potential decision to move into dose expansions in 2025.
04/03 08:00 EST - globenewswire.com
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date -
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date -
03/21 08:00 EST - globenewswire.com
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors.
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors.
03/18 08:00 EST - globenewswire.com
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX -
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX -